Abstract
Interleukin (IL)-12 and antibodies against CD40 have demonstrated antitumor effects in a variety of in vivo model systems. However, both agents can also mediate significant toxicities either when used following lethal TBI or when administered in combination with other agents such as IL-2. In this study, we assessed the effects of anti-CD40 monoclonal antibody (MoAb) and IL-12 in lethally irradiated mice. Acute lethal toxicity was observed following the administration of either 10 μg anti-CD40 MoAb (FGK45) or 0.5 μg of recombinant murine (rm)IL-12 that resulted in 100% mortality of all mice within 4 to 6 days. Histological evaluation revealed destruction of the normal gut architecture in both anti-CD40 MoAb- and rmIL-12-treated mice. Analysis of serum cytokine levels in the lethally irradiated mice receiving anti-CD40 MoAb demonstrated a marked increase of interferon (IFN)-γ and IL-12 p40, whereas mice receiving rmIL-12 demonstrated a marked increase of IFN-γ. Lethally irradiated IL-12 p40 knock-out mice were resistant to anti-CD40-induced toxicity, suggesting that the lack of IL-12 p40 with no possibility of making functional IL-12 p70 is key for this toxic reaction. Similarly, lethally irradiated IFN-γ knock-out mice were completely resistant to rmIL-12-induced toxicity, suggesting that IFN-γ is a major player in IL-12-mediated toxicity. These results suggest that both anti-CD40 MoAb and rmIL-12 induce an acute fatal toxicity characterized by similar intestinal pathology and mediated in part by IFN-γ.
Original language | English (US) |
---|---|
Pages (from-to) | 316-325 |
Number of pages | 10 |
Journal | Biology of Blood and Marrow Transplantation |
Volume | 8 |
Issue number | 6 |
DOIs | |
State | Published - 2002 |
Externally published | Yes |
Bibliographical note
Funding Information:This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract no. N01-CO-124000 and supported in part by National Institutes of Health Grants RO1 AI34495, RO1 HL63452, and R37 HL56067.
Keywords
- Antibodies
- Cytokines
- In vivo animal models
- Transplantation